Τίτλος:
Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients.
Συγγραφείς:
Tsirigotis, P.
Danylesko, I.
Gkirkas, K.
Shem-Tov, N.
Yerushalmi, R.
Stamouli, M.
Avigdor, A.
Spyridonidis, A.
Gauthier, J.
Goldstein, G.
Apostolidis, J.
Mohty, M.
Shimoni, A.
Nagler, A.
Περιοδικό:
Bone marrow transplantation. Supplement (Basingstoke)
Εκδότης:
Nature Publishing Group
Λέξεις-κλειδιά:
alemtuzumab; bendamustine; brentuximab vedotin; chlorambucil; fludarabine; melphalan; procarbazine; steroid; thiotepa; treosulfan; valganciclovir; vincristine; antibody conjugate; brentuximab vedotin; steroid, adolescent; adult; allogeneic stem cell transplantation; Article; cancer recurrence; cancer survival; chronic graft versus host disease; clinical article; clinical effectiveness; consolidation chemotherapy; controlled study; cytomegalovirus infection; diarrhea; disease severity; donor lymphocyte infusion; drug megadose; drug safety; drug tolerability; drug withdrawal; female; fever; follow up; Hodgkin disease; human; immunosuppressive treatment; low drug dose; male; multicenter study (topic); multiple cycle treatment; neutropenia; peripheral neuropathy; priority journal; progression free survival; thrombocytopenia; treatment duration; treatment response; virus reactivation; young adult; clinical trial; complication; evaluation study; graft versus host reaction; hematopoietic stem cell transplantation; Hodgkin disease; lymphocyte transfusion; mortality; multicenter study; multimodality cancer therapy; procedures; survival analysis; treatment outcome, Adolescent; Adult; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lymphocyte Transfusion; Male; Steroids; Survival Analysis; Treatment Outcome; Young Adult
DOI:
10.1038/bmt.2016.129
